289 related articles for article (PubMed ID: 16555680)
1. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
[TBL] [Abstract][Full Text] [Related]
3. Are vitamin D receptor activators useful for the treatment of thrombosis?
Wu-Wong JR
Curr Opin Investig Drugs; 2009 Sep; 10(9):919-27. PubMed ID: 19705334
[TBL] [Abstract][Full Text] [Related]
4. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
Wu-Wong JR; Melnick J
Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D analogs as therapeutic agents: a clinical study update.
Wu-Wong JR; Tian J; Goltzman D
Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
[TBL] [Abstract][Full Text] [Related]
6. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells.
Wu-Wong JR; Nakane M; Ma J
Thromb Res; 2006; 118(6):709-14. PubMed ID: 16371233
[TBL] [Abstract][Full Text] [Related]
7. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells.
Wu-Wong JR; Nakane M; Ma J; Ruan X; Kroeger PE
J Cell Biochem; 2007 Apr; 100(6):1395-405. PubMed ID: 17115413
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease.
Franczyk A; Stolarz-Skrzypek K; Wesołowska A; Czarnecka D
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):34-44. PubMed ID: 24597598
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
11. Endothelial dysfunction and chronic kidney disease: treatment options.
Wu-Wong JR
Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
[TBL] [Abstract][Full Text] [Related]
12. Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells.
Wu-Wong JR; Nakane M; Ma J; Ruan X; Kroeger PE
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1592-604. PubMed ID: 17715259
[TBL] [Abstract][Full Text] [Related]
13. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
Goldenberg MM
Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
[TBL] [Abstract][Full Text] [Related]
14. [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
Dusilová Sulková S
Vnitr Lek; 2012 Nov; 58(11):839-49. PubMed ID: 23256830
[TBL] [Abstract][Full Text] [Related]
15. Role of vitamin D in cardiovascular disease.
Verhave G; Siegert CE
Neth J Med; 2010 Mar; 68(3):113-8. PubMed ID: 20308705
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs: novel therapeutic agents for cardiovascular disease?
Reinhart GA
Curr Opin Investig Drugs; 2004 Sep; 5(9):947-51. PubMed ID: 15503649
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D: an old prohormone with an emergent role in chronic kidney disease.
Coen G
J Nephrol; 2008; 21(3):313-23. PubMed ID: 18587719
[TBL] [Abstract][Full Text] [Related]
18. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.
Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J
Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D receptor ligand therapy in chronic kidney disease.
Gonzalez E
Clin Nephrol; 2008 Oct; 70(4):271-83. PubMed ID: 18826852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
